BR0202759A - Composição farmacêutica de liberação modificada contendo bupropiona como substância ativa - Google Patents

Composição farmacêutica de liberação modificada contendo bupropiona como substância ativa

Info

Publication number
BR0202759A
BR0202759A BR0202759-3A BR0202759A BR0202759A BR 0202759 A BR0202759 A BR 0202759A BR 0202759 A BR0202759 A BR 0202759A BR 0202759 A BR0202759 A BR 0202759A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
active substance
modified release
composition containing
containing bupropion
Prior art date
Application number
BR0202759-3A
Other languages
English (en)
Inventor
Roberto Valducci
Tiziano Alighieri
Serozh Avanessian
Original Assignee
Valpharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valpharma Sa filed Critical Valpharma Sa
Publication of BR0202759A publication Critical patent/BR0202759A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA DE LIBERAçãO MODIFICADA CONTENDO BUPROPIONA COMO SUBSTâNCIA ATIVA". Composição farmacêutica em forma de comprimido de liberação modificada contendo Bupropiona HCI como substância ativa e incluindo, ao mesmo tempo, componentes hidrofílicos e ingredientes hidrofóbicos misturados com uma substância excipiente.
BR0202759-3A 2001-07-09 2002-07-05 Composição farmacêutica de liberação modificada contendo bupropiona como substância ativa BR0202759A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI001457A ITMI20011457A1 (it) 2001-07-09 2001-07-09 Composizione farmaceutica a rilascio modificato contenente bupropionehc1 come sostanza attiva
CA002391691A CA2391691A1 (en) 2001-07-09 2002-06-26 Modified release pharmaceutical composition containing bupropion hci as active substance

Publications (1)

Publication Number Publication Date
BR0202759A true BR0202759A (pt) 2004-05-11

Family

ID=32991642

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0202759-3A BR0202759A (pt) 2001-07-09 2002-07-05 Composição farmacêutica de liberação modificada contendo bupropiona como substância ativa

Country Status (14)

Country Link
US (1) US20030134906A1 (pt)
EP (1) EP1275383B1 (pt)
JP (1) JP2003048828A (pt)
AT (1) ATE262898T1 (pt)
AU (1) AU5068202A (pt)
BR (1) BR0202759A (pt)
CA (1) CA2391691A1 (pt)
DE (1) DE60200317T2 (pt)
DK (1) DK1275383T3 (pt)
ES (1) ES2219602T3 (pt)
IL (1) IL149899A0 (pt)
IT (1) ITMI20011457A1 (pt)
NZ (1) NZ519844A (pt)
PT (1) PT1275383E (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN192747B (pt) * 2002-04-15 2004-05-15 Ranbaxy Lab Ltd
KR101087464B1 (ko) * 2003-08-08 2011-11-25 밸리언트 인터내셔널(바베이도스) 에스알엘 부프로피온 히드로클로라이드의 개질 방출형 정제
US8691272B2 (en) * 2005-12-30 2014-04-08 Intelgenx Corp. Multilayer tablet

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393078A (en) * 1982-03-15 1983-07-12 Burroughs Wellcome Co. Bupropion and ethanol
USRE33994E (en) * 1983-08-16 1992-07-14 Burroughs Wellcome Co. Pharmaceutical delivery system
GB9217295D0 (en) * 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) * 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
JP2001527554A (ja) * 1997-05-07 2001-12-25 アルゴス ファーマシューティカル コーポレーション 抗うつ薬とｎｍｄａレセプター拮抗薬とを組み合わせる神経障害痛の治療用組成物及び治療方法
ES2248908T7 (es) * 1997-06-06 2014-11-24 Depomed, Inc. Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
US6635280B2 (en) * 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
CA2244097A1 (en) * 1998-08-21 2000-02-21 Bernard Charles Sherman Pharmaceutical composition comprising bupropion hydrochloride and fumaric acid
US6096341A (en) * 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
US6238697B1 (en) * 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
US6210716B1 (en) * 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation

Also Published As

Publication number Publication date
DK1275383T3 (da) 2004-05-24
ATE262898T1 (de) 2004-04-15
AU5068202A (en) 2003-01-16
NZ519844A (en) 2003-09-26
ITMI20011457A1 (it) 2003-01-09
EP1275383A1 (en) 2003-01-15
PT1275383E (pt) 2004-06-30
EP1275383B1 (en) 2004-03-31
ITMI20011457A0 (it) 2001-07-09
IL149899A0 (en) 2002-11-10
ES2219602T3 (es) 2004-12-01
US20030134906A1 (en) 2003-07-17
JP2003048828A (ja) 2003-02-21
DE60200317D1 (de) 2004-05-06
DE60200317T2 (de) 2005-02-24
CA2391691A1 (en) 2003-12-26

Similar Documents

Publication Publication Date Title
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
PT1283700E (pt) Composicoes farmaceuticas de libertacao prolongada destinadas a administracao por via parental de compostos hidrofilos biologicamente activos
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
IL163552A (en) Conjugates of biologically active compounds, uses thereof and pharmaceutical compositions comprising the same
BR0107869A (pt) Composições farmacêuticas eletrogiradas
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
ZA200307161B (en) Medical aerosol formulations
BR0112962B1 (pt) Composições farmacêuticas compreendendo ácido hialurônico, ácido glicirretínico e polivinilpirrolidona, e uso desses compostos na preparação de medicamentos
DE60131760D1 (de) Vorrichtung zur verabreichung von physiologisch aktiven wirkstoffen in pulverform
MY143795A (en) Tetrahydropyridoindole derivatives
GEP20063818B (en) Orodispersible pharmaceutical composition comprising agomelatine
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
CY1107752T1 (el) Xρηση των εξενδινων και αγωνιστων τους για τη θεραπεια του σακχαρωδους διαβητη της κυησης
MA28844B1 (fr) Composition pharmaceutique comprenant de la drospirenone et de l'ethynylestradiol
DE60202590D1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
GEP20063820B (en) Orodispersible pharmaceutical composition comprising ivabradine
HRP20050342B1 (hr) Farmaceutska formulacija olanzapina
EA200901148A1 (ru) Подкожные имплантаты, высвобождающие активные компоненты в течение длительного периода времени
SE0001916D0 (sv) Novel formulation
ATE245974T1 (de) Pharmazeutische zusammensetzungen, bestimmt zur oralen verabreichung von phloroglucinol sowie deren herstellung
PT1275383E (pt) Composicao farmaceutica de libertacao modificada que contem bupropion hc1 como substancia activa
WO2002066492A3 (fr) Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques.
AR046955A1 (es) Preparacion efervescente de una sustancia basica farmaceuticamente activa
ATE382363T1 (de) Pharmazeutische zusammensetzung enthaltend bulbophyllum
CL2004000633A1 (es) Compuestos copolimeros, composicion farmaceutica que los contiene y procedimiento de preparacion, utiles en el tratamiento de enfermedades metabolicas oseas.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]